Impact of medications prescribed for treatment of attention-deficit hyperactivity disorder on physical growth in children and adolescents with HIV

Patricia A. Sirois, Grace Montepiedra, Suad Kapetanovic, Paige L. Williams, Deborah A. Pearson, Kathleen M Malee, Patricia A. Garvie, Betsy L. Kammerer, Sharon L. Nichols, Molly L. Nozyce, Mark Mintz, Wendy G. Mitchell, James M. Oleske

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Objective: To examine the relationships between physical growth and medications prescribed for symptoms of attention-deficit hyperactivity disorder in children with HIV. Methods: Analysis of data from children with perinatally acquired HIV (N = 2251; age 3-19 years), with and without prescriptions for stimulant and nonstimulant medications used to treat attention-deficit hyperactivity disorder, in a long-term observational study. Height and weight measurements were transformed to z scores and compared across medication groups. Changes in z scores during a 2-year interval were compared using multiple linear regression models adjusting for selected covariates. Results: Participants with (n = 215) and without (n = 2036) prescriptions were shorter than expected based on US age and gender norms (p < .001). Children without prescriptions weighed less at baseline than children in the general population (p < .001) but gained height and weight at a faster rate (p < .001). Children prescribed stimulants were similar to population norms in baseline weight; their height and weight growth velocities were comparable with the general population and children without prescriptions (for weight, p = .511 and .100, respectively). Children prescribed nonstimulants had the lowest baseline height but were similar to population norms in baseline weight. Their height and weight growth velocities were comparable with the general population but significantly slower than children without prescriptions (p = .01 and .02, respectively). Conclusion: The use of stimulants to treat symptoms of attention-deficit hyperactivity disorder does not significantly exacerbate the potential for growth delay in children with HIV and may afford opportunities for interventions that promote physical growth. Prospective studies are needed to confirm these findings.

Original languageEnglish (US)
Pages (from-to)403-412
Number of pages10
JournalJournal of Developmental and Behavioral Pediatrics
Volume30
Issue number5
DOIs
StatePublished - Oct 2009

Keywords

  • ADHD medication side effects
  • Children and adolescents
  • HIV/AIDS
  • Height
  • Weight

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Developmental and Educational Psychology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Impact of medications prescribed for treatment of attention-deficit hyperactivity disorder on physical growth in children and adolescents with HIV'. Together they form a unique fingerprint.

  • Cite this

    Sirois, P. A., Montepiedra, G., Kapetanovic, S., Williams, P. L., Pearson, D. A., Malee, K. M., Garvie, P. A., Kammerer, B. L., Nichols, S. L., Nozyce, M. L., Mintz, M., Mitchell, W. G., & Oleske, J. M. (2009). Impact of medications prescribed for treatment of attention-deficit hyperactivity disorder on physical growth in children and adolescents with HIV. Journal of Developmental and Behavioral Pediatrics, 30(5), 403-412. https://doi.org/10.1097/DBP.0b013e3181ba0cf6